GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (STU:HDP1) » Definitions » Cyclically Adjusted PB Ratio

Arrowhead Pharmaceuticals (STU:HDP1) Cyclically Adjusted PB Ratio : 7.65 (As of May. 26, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Arrowhead Pharmaceuticals's current share price is €22.88. Arrowhead Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €2.99. Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 7.65.

The historical rank and industry rank for Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:HDP1' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.12   Med: 8.38   Max: 43.2
Current: 7.68

During the past years, Arrowhead Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 43.20. The lowest was 0.12. And the median was 8.38.

STU:HDP1's Cyclically Adjusted PB Ratio is ranked worse than
86.06% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs STU:HDP1: 7.68

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Arrowhead Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €3.586. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.99 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.66 20.93 25.78 11.44 8.27

Arrowhead Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.18 11.19 8.27 9.54 8.83

Competitive Comparison of Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=22.88/2.99
=7.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Arrowhead Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.586/131.7762*131.7762
=3.586

Current CPI (Mar. 2024) = 131.7762.

Arrowhead Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.592 100.560 3.397
201409 2.364 100.428 3.102
201412 2.168 99.070 2.884
201503 2.250 99.621 2.976
201506 1.966 100.684 2.573
201509 1.649 100.392 2.165
201512 1.431 99.792 1.890
201603 1.115 100.470 1.462
201606 0.883 101.688 1.144
201609 1.221 101.861 1.580
201612 1.245 101.863 1.611
201703 1.174 102.862 1.504
201706 1.072 103.349 1.367
201709 0.913 104.136 1.155
201712 0.798 104.011 1.011
201803 1.058 105.290 1.324
201806 0.997 106.317 1.236
201809 0.928 106.507 1.148
201812 1.633 105.998 2.030
201903 1.881 107.251 2.311
201906 2.103 108.070 2.564
201909 2.325 108.329 2.828
201912 4.451 108.420 5.410
202003 4.395 108.902 5.318
202006 4.283 108.767 5.189
202009 3.830 109.815 4.596
202012 3.620 109.897 4.341
202103 3.598 111.754 4.243
202106 3.480 114.631 4.000
202109 3.331 115.734 3.793
202112 3.146 117.630 3.524
202203 3.885 121.301 4.220
202206 4.059 125.017 4.278
202209 3.799 125.227 3.998
202212 3.353 125.222 3.529
202303 3.905 127.348 4.041
202306 3.144 128.729 3.218
202309 2.369 129.860 2.404
202312 1.368 129.419 1.393
202403 3.586 131.776 3.586

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arrowhead Pharmaceuticals  (STU:HDP1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals (STU:HDP1) Business Description

Traded in Other Exchanges
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Arrowhead Pharmaceuticals (STU:HDP1) Headlines

No Headlines